Eczema Prognosis — source conflicts

Conflict: [Kim et al., JAAD 2016] says 80% of childhood AD has remitted by 8 years after diagnosis and <5% persists at 20 years. [Margolis et al., JAMA Dermatol 2014, PEER registry] says >80% of children aged 2–26 still had symptoms or used treatment, and only half had a 6-month clear spell by age 20. [Abuabara et al., Allergy 2018] found AD prevalence barely falls after age 12 (−1%, not significant), and [Abuabara et al., JACI 2019, British 1958/1970 cohorts] found 5–15% annual prevalence with no clear decline to midlife and only 38% of adult cases with childhood onset. [Illi et al., JACI 2004, MAS] found 43% of early AD fully remitted by age 3 but 19% had symptoms every year to age 7. Unresolved — add to open_questions. (Extends atopic-dermatitis-conflicts.md entry.)

Conflict: [Kim et al., JAAD 2016] says onset by age 2 predicts less persistent AD and sensitisation is not associated with persistence (P = .90). [Paternoster et al., JACI 2018] says both long-lasting classes are early-onset with the strongest FLG/family-history links; [Illi et al., JACI 2004] says atopic sensitisation is a major determinant of poor prognosis (aOR 2.76); [Medicina 2024] lists younger onset age as a progression risk factor. Unresolved — add to open_questions.

Conflict: [Classic atopic-march model, CHILD/PASTURE/DBH cited in Medicina 2024] says early AD precedes and raises later asthma. [Illi et al., JACI 2004; Paternoster et al., JACI 2018] say AD-plus-wheeze is a distinct co-occurring phenotype and the data do not support a specific AD→asthma trajectory. Unresolved — add to open_questions.